First-line immune-checkpoint inhibitor plus chemotherapy
chemotherapy
immunotherapy
meta-analysis
small-cell lung cancer
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2020
2020
Historique:
received:
21
09
2020
accepted:
05
11
2020
entrez:
21
12
2020
pubmed:
22
12
2020
medline:
22
12
2020
Statut:
epublish
Résumé
Platin-based chemotherapy (CT) has long been the first-line standard-of-care for patients with extensive-stage small-cell lung cancer (ES-SCLC). Adding immune-checkpoint inhibitor(s) to CT (ICI+CT) in this setting is an option of interest, although its benefit is apparently modest. This meta-analysis was conducted on randomized trials comparing first-line ICI+CT The literature search identified one randomized phase II (ECOG-ACRIN-5161) and four phase III trials (CASPIAN, IMPOWER-133, KEYNOTE-604 and Reck First-line ICI+CT appears to be superior to CT alone for ES-SCLC except for patients with brain metastases at diagnosis.
Identifiants
pubmed: 33343721
doi: 10.1177/1758835920977137
pii: 10.1177_1758835920977137
pmc: PMC7731693
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1758835920977137Informations de copyright
© The Author(s), 2020.
Déclaration de conflit d'intérêts
Conflict of interest statement: The authors declare that there is no conflict of interest.
Références
Lancet Oncol. 2016 Jul;17(7):883-895
pubmed: 27269741
J Clin Oncol. 2012 May 10;30(14):1692-8
pubmed: 22473169
Front Oncol. 2019 Apr 16;9:264
pubmed: 31058078
J Thorac Oncol. 2018 Sep;13(9):1393-1399
pubmed: 29775808
Neoplasia. 2017 Oct;19(10):842-847
pubmed: 28888101
J Thorac Oncol. 2020 Apr;15(4):618-627
pubmed: 31870883
Clin Lung Cancer. 2007 Sep;8(8):497-501
pubmed: 17922975
J Thorac Oncol. 2019 May;14(5):768-783
pubmed: 30763729
J Clin Oncol. 2020 Jul 20;38(21):2369-2379
pubmed: 32468956
J Immunother Cancer. 2018 Dec 3;6(1):135
pubmed: 30509312
Oncol Rev. 2020 Jul 21;14(2):490
pubmed: 32782728
N Engl J Med. 2018 Dec 6;379(23):2220-2229
pubmed: 30280641
J Clin Oncol. 2016 Nov 1;34(31):3740-3748
pubmed: 27458307
Lancet. 2019 Nov 23;394(10212):1929-1939
pubmed: 31590988
J Clin Oncol. 2002 Dec 15;20(24):4665-72
pubmed: 12488411